The struggling Minnesota company made a last-ditch effort to complete the eMESH 1 trial of the eSVS Mesh device for coronary artery bypass graft surgery, but the firm, founded by device sector luminary Manny Villafana, has decided to give it up after the early results from the trial proved disappointing.
Kips Bay Medical Inc. is shutting down operations after reviewing the early results of the eMESH I feasibility trial of its eSVS Mesh for coronary bypass graft surgery, the firm announced June 29.
In January, the Minnesota company announced that it cut its staff from 13 to eight, and temporarily reduced salaries for...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Joshi joins the parent company of Citeline, home of Medtech Insight, to focus on AI, business harmonization and long-term growth.
A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.
CMS is proposing to classify all CGMs and insulin pumps as “items requiring frequent and substantial servicing” to expand device choice and access for Medicare beneficiaries. Under this framework, CMS also intends to move Class II devices, which include CGMs from Abbott and Dexcom and pumps from Tan
